Literature DB >> 6607146

Lymphocytotoxic antibodies in the acquired immune deficiency syndrome (AIDS).

B E Kloster, R H Tomar, T J Spira.   

Abstract

The acquired immune deficiency syndrome (AIDS) manifested by opportunistic infections or Kaposi's sarcoma is a newly recognized and often fatal disease. Three patients seen in Syracuse, New York, were noted to have lymphopenia and persistent serum lymphocytotoxic antibodies (LCTAs). In a double blinded study, 25 serum samples were coded and sent to us by the Centers for Disease Control Task Force on Kaposi's Sarcoma and Opportunistic Infections. Samples from 5 patients with Pneumocystis carinii pneumonia, 5 patients with Kaposi's sarcoma, 5 presumably healthy homosexual males, 5 presumably healthy heterosexual males, and 5 presumably healthy heterosexual females were included. Of the ten AIDS patients, nine had "positive" or "suspicious" results on testing for lymphocytotoxic antibodies. The five heterosexual male and five heterosexual female controls had "negative" results. Of the five homosexual male "controls," three had "positive" or "suspicious" LCTA results. Two of these three "controls" were available for follow-up. Both showed deficiencies in studies of their cell-mediated immunity. Lymphocytotoxic antibodies may participate in the ongoing immunodeficiency seen in AIDS.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6607146     DOI: 10.1016/0090-1229(84)90066-7

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  16 in total

Review 1.  Molecular mimicry as a mechanism for virus-induced autoimmunity.

Authors:  R S Fujinami; M B Oldstone
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

Review 2.  Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date.

Authors:  E G Sandström; J C Kaplan
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

3.  Densitometric analysis of Western blot (immunoblot) assays for human immunodeficiency virus antibodies and correlation with clinical status.

Authors:  G Schmidt; K Amiraian; H Frey; R W Stevens; D S Berns
Journal:  J Clin Microbiol       Date:  1987-10       Impact factor: 5.948

4.  Serum lymphocytotoxic activity in leprosy.

Authors:  F N Rasheed; M Locniskar; D J McCloskey; R S Hasan; T J Chiang; P Rose; R de Soldenhoff; H Festenstein; K P McAdam
Journal:  Clin Exp Immunol       Date:  1989-06       Impact factor: 4.330

5.  Humoral-mediated suppression of interleukin 2-dependent target cell proliferation in acquired immune deficiency syndrome (AIDS): interference with normal IL-2 receptor expression.

Authors:  R P Donnelly; M F La Via; K Y Tsang
Journal:  Clin Exp Immunol       Date:  1987-06       Impact factor: 4.330

6.  The significance of antilymphocyte antibodies in patients with acquired immune deficiency syndrome (AIDS) and their sexual partners.

Authors:  G E Ozturk; P F Kohler; C R Horsburgh; C H Kirkpatrick
Journal:  J Clin Immunol       Date:  1987-03       Impact factor: 8.317

7.  Heightened complement sensitivity of acquired immunodeficiency syndrome lymphocytes related to diminished expression of decay-accelerating factor.

Authors:  M M Lederman; S F Purvis; E I Walter; J T Carey; M E Medof
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

Review 8.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

9.  Anti-lymphocyte antibodies in plasma of HIV-1-infected patients preferentially react with MHC class II-negative T cells and are linked to antibodies against gp41.

Authors:  C Müller; S Kukel; K E Schneweis; R Bauer
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

10.  Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV.

Authors:  A M Prince; B Horowitz; L Baker; R W Shulman; H Ralph; J Valinsky; A Cundell; B Brotman; W Boehle; F Rey
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.